|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2013. View Article : Google Scholar
|
|
2
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ,
Van Schil PE, et al: International Association for the Study of
Lung Cancer/American Thoracic Society/European Respiratory Society:
International multidisciplinary classification of lung
adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chhieng DC, Cangiarella JF, Zakowski MF,
Goswami S, Cohen JM and Yee HT: Use of thyroid transcription factor
1, PE-10 and, cytokeratins 7 and 20 in discriminating between
primary lung carcinomas and metastatic lesions in fine-needle
aspiration biopsy specimens. Cancer. 93:330–336. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ueno T, Linder S and Elmberger G: Aspartic
proteinase napsin is a useful marker for diagnosis of primary lung
adenocarcinoma. Br J Cancer. 88:1229–1233. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Barbareschi M, Murer B, Colby TV, Chilosi
M, Macri E, Loda M and Doglioni C: CDX-2 homeobox gene expression
is a reliable marker of colorectal adenocarcinoma metastases to the
lungs. Am J Surg Pathol. 27:141–149. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ho SB, Shekels LL, Toribara NW, Kim YS,
Lyftogt C, Cherwitz DL and Niehans GA: Mucin gene expression in
normal, preneoplastic and neoplastic human gastric epithelium.
Cancer Res. 55:2681–2690. 1995.PubMed/NCBI
|
|
7
|
Lau SK, Weiss LM and Chu PG: Differential
expression of MUC1, MUC2 and MUC5AC in carcinomas of various sites:
An immunohistochemical study. Am J Clin Pathol. 122:61–69. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Min KW: Two different types of carcinoid
tumors of the lung: Immunohistochemical and ultrastructural
investigation and their histogenetic consideration. Ultrastruct
Pathol. 37:23–35. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger K, Yatabe Y, Ishikawa Y, Wistuba I, Flieder
DB, Franklin W, et al: Diagnosis of lung adenocarcinoma in resected
specimens: Implications of the 2011 International association for
the Study of lung Cancer/American Thoracic Society/European
Respiratory Society classification. Arch Pathol Lab Med.
137:685–705. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ou SH, Kawaguchi T, Soo RA and Kitaichi M:
Rare subtypes of adenocarcinoma of the lung. Expert Rev Anticancer
Ther. 11:1535–1542. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Inamura K, Satoh Y, Okumura S, Nakagawa K,
Tsuchiya E, Fukayama M and Ishikawa Y: Pulmonary adenocarcinomas
with enteric differentiation: Histologic and immunohistochemical
characteristics compared with metastatic colorectal cancers and
usual pulmonary adenocarcinomas. Am J Surg Pathol. 29:660–665.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yousem SA: Pulmonary intestinal-type
adenocarcinoma does not show enteric differentiation by
immunohistochemical study. Mod Pathol. 18:816–821. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Maeda R, Isowa N, Onuma H and Miura H:
Pulmonary intestinal-type adenocarcinoma. Interact Cardiovasc
Thorac Surg. 7:349–351. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li HC, Schmidt L, Greenson JK, Chang AC
and Myers JL: Primary pulmonary adenocarcinoma with intestinal
differentiation mimicking metastatic colorectal carcinoma. Am J
Clin Pathol. 131:129–133. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hatanaka K, Tsuta K, Watanabe K, Sugino K
and Uekusa T: Primary pulmonary adenocarcinoma with enteric
differentiation resembling metastatic colorectal carcinoma: A
report of the second case negative for cytokeratin 7. Pathol Res
Pract. 207:188–191. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin D, Zhao Y, Li H and Xing X: Pulmonary
enteric adenocarcinoma with villin brush border immunoreactivity: A
case report and literature review. J Thorac Dis. 5:E17–E20.
2013.PubMed/NCBI
|
|
17
|
Stojsic J, Kontic M, Subotic D, Popovic M,
Tomasevic D and Lukic J: Intestinal type of lung adenocarcinoma in
younger adults. Case Rep Pulmonol. 2014:2821962014.PubMed/NCBI
|
|
18
|
Qureshi A and Furrukh M: Enteric
adenocarcinoma lung: A rare presentation in an Omani woman. BMJ
Case Rep. 25:doi: 10.1136/bcr-2012-007667. 2013.
|
|
19
|
Wang CX, Liu B, Wang YF, Zhang RS, Yu B,
Lu ZF, Shi QL and Zhou XJ: Pulmonary enteric adenocarcinoma: A
study of the clinicopathologic and molecular status of nine cases.
Int J Clin Exp Pathol. 7:1266–1274. 2014.PubMed/NCBI
|
|
20
|
Remo A, Zanella C, Pancione M, Astati L,
Piacentini P, Cingarlini S, Bonetti A, Micheletto C, Talamini A,
Chilosi M, et al: Lung metastasis from TTF-1 positive sigmoid
adenocarcinoma. Pitfalls and management. Pathologica. 105:69–72.
2013.PubMed/NCBI
|
|
21
|
Sullivan LM, Smolkin ME, Frierson HF Jr
and Galgano MT: Comprehensive evaluation of CDX2 in invasive
cervical adenocarcinomas: Immunopositivity in the absence of overt
colorectal morphology. Am J Surg Pathol. 32:1608–1612. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tsao MS and Fraser RS: Primary pulmonary
adenocarcinoma with enteric differentiation. Cancer. 68:1754–1757.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Satoh Y, Hoshi R, Tsuzuku M, Ishikawa Y,
Inamura K and Horai T: Cytology of pulmonary adenocarcinomas
showing enteric differentiation. Acta Cytol. 50:250–256. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nagasaka T, Sasamoto H, Notohara K,
Cullings HM, Takeda M, Kimura K, Kambara T, MacPhee DG, Young J,
Leggett BA, et al: Colorectal cancer with mutation in BRAF, KRAS,
and wild-type with respect to both oncogenes showing different
patterns of DNA methylation. J Clin Oncol. 22:4584–4594. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Moran T, Wei J, Cobo M, Qian X, Domine M,
Zou Z, Bover I, Wang L, Provencio M, Yu L, et al: Spanish Lung
Cancer Group; French Lung Cancer Group; Comprehensive Cncer Centre
of Drum Tower Hospital in Nanjing: Two biomarker-directed
randomized trials in European and Chinese patients with
nonsmall-cell lung cancer: The BRCA1-RAP80 expression customization
(BREC) studies. Ann Oncol. 25:2147–2155. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bonanno L, Costa C, Majem M, Favaretto A,
Rugge M and Rosell R: The predictive value of BRCA1 and RAP80 mRNA
expression in advanced non-small-cell lung cancer patients treated
with platinum-based chemotherapy. Ann Oncol. 24:1130–1132. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Olaussen KA, Dunant A, Fouret P, Brambilla
E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH,
et al: IALT Bio Investigators: DNA repair by ERCC1 in
non-small-cell lung cancer and cisplatin-based adjuvant
chemotherapy. N Engl J Med. 355:983–991. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Reynolds C, Obasaju C, Schell MJ, Li X,
Zheng Z, Boulware D, Caton JR, Demarco LCO, Rourke MA, Shaw Wright
G, et al: Randomized phase III trial of gemcitabine-based
chemotherapy with in situ RRM1 and ERCC1 protein levels for
response prediction in non-small-cell lung cancer. J Clin Oncol.
27:5808–5815. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bepler G, Sommers KE, Cantor A, Li X,
Sharma A, Williams C, Chiappori A, Haura E, Antonia S, Tanvetyanon
T, et al: Clinical efficacy and predictive molecular markers of
neoadjuvant gemcitabine and pemetrexed in resectable non-small cell
lung cancer. J Thorac Oncol. 3:1112–1118. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
André T, Bensmaine MA, Louvet C, François
E, Lucas V, Desseigne F, Beerblock K, Bouché O, Carola E, Merrouche
Y, et al: Multicenter phase II study of bimonthly high-dose
leucovorin, fluorouracil infusion, and oxaliplatin for metastatic
colorectal cancer resistant to the same leucovorin and fluorouracil
regimen. J Clin Oncol. 17:3560–3568. 1999.PubMed/NCBI
|
|
31
|
Saltz LB, Cox JV, Blanke C, Rosen LS,
Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta
N, et al: Irinotecan plus fluorouracil and leucovorin for
metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med.
343:905–914. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang K, Vaughn DJ, Shaw LM, Recio A,
Bonner HS and Haller DG: A phase II trial and pharmacokinetic
analysis of 96-hour infusional paclitaxel in patients with
metastatic colorectal cancer. Am J Clin Oncol. 21:548–552. 1998.
View Article : Google Scholar : PubMed/NCBI
|
